Merck Buys Mirus Bio for $600 Million

Merck expands. The German multinational has signed the definitive agreement to acquire Mirus Bio for $600 million (about 550 million euros) . The president of the executive board and CEO of Merck, the Spanish Belén Garijo, has declared that this is a strategic acquisition to “accelerate the growth of the revolutionary technologies of the future.”

The first executive explained that her objective is “to make the important potential of cell and gene therapy available to patients around the world. ”

For his part, the CEO of Mirus Bio stated: “ We have been promoting innovation in the administration of nucleic acids for two decades; “Merck’s broad portfolio, scale and global reach, combined with our leading transfection reagents, will allow us to serve more customers and help more patients around the world.”

“This purchase will help us accelerate the growth of the revolutionary technologies of the future” Merck says

As they have conveyed in a statement, “ the acquisition of Mirus Bio is an important step for Merck to offer solutions for each and every step of viral vector manufacturing to advance cell and gene therapies, from the preclinical phase to commercial production.

Cellular and gene therapies, antibody conjugate drugs or mRNA, are modalities that are generating lucrative markets for the pharmaceutical sector . According to Merck’s statement, “the global market for process products for these modalities is expected to grow around 20% annually ; “The number of cell and gene therapies in development has doubled since 2019, and more and more are advancing to the commercial phase.”

To support the bet, Merck opened its second viral vector manufacturing plant in 2021, California. The one hundred million euro investment doubled the company’s ability to support large-scale commercial and industrial manufacturing of these therapies. They also invest in research and development “so that their clients can market new curative treatments.”

__

(Featured image by Precondo CA via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us